Offering Prenatal Screening in the Age of Genomic Medicine: A Practical Guide
Published July 2017
Summary: In September 2015, Mayo Clinic convened a panel of national thought leaders on prenatal screening, medical genetics, and obstetrics and gynecology practice. Participants discussed the implications of the shift toward broader prenatal screening using cell-free placental DNA in maternal serum. Key topics included challenges around the pace of change in the prenatal screening market, uncertainty around reimbursement, meeting the need for patient counseling, and potential challenges in interpreting and returning results. Here, we describe these challenges and offer clinical recommendations to meet them.
Citation and link:
Allyse M, Aypar U, Bonhomme N, Darilek S, Dougherty M, Farrell R, Grody W, Highsmith E, Jr., Michie M, Nunes M, Pabst R, Palomaki G, Runke C, Sharp R, Skotko B, Stoll K, Wick M. (2017) Offering prenatal screening in the age of genomic medicine: A practical guide. Journal of Women’s Health 26(7):755-761. http://dx.doi.org/10.1089/jwh.2016.6098